Research Reports

Key takeaways

Benoit Gourdier, EVP Bioscience and Medtech Products, transitioning to segment integration support role on April 17, 2026, with departure expected no later than December 31, 2026.

Ludovic Brellier hired as EVP Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026.

Brellier joins from Danaher's Cytiva where he was President of Hardware Solutions, with prior roles in integrated solutions and business operations.

Brellier to grow BMP business, improve operations, and lead Revival Management Office transformation initiatives.

Gourdier to remain until end of 2026 for smooth transition.

CEO Emmanuel Ligner highlights Brellier's track record in bioprocessing growth and transformation experience.

Full analysis

The leadership change in Avantor's Bioscience and Medtech Products (BMP) segment involves EVP Benoit Gourdier moving to a temporary integration support role starting April 17, 2026, with an expected exit by year-end to facilitate a seamless handover. Succeeding him is Ludovic Brellier, effective May 1, 2026, bringing extensive experience from Danaher's Cytiva, including leading hardware solutions, integrated services, and key integrations like Pall Life Sciences. Brellier's dual mandate to drive BMP growth—both organic and inorganic—and spearhead enterprise-wide transformation via the Revival Management Office underscores strategic focus on operational enhancements and bioprocessing expansion. CEO Emmanuel Ligner emphasized Brellier's proven ability to scale businesses, positioning the BMP segment for accelerated potential amid ongoing revival efforts.

AVTR · Avantor, Inc.

Summary

Key takeaways

Full analysis